Drug intelligence / Profile preview

PBCLN-010

Development stage: Unknown
Lead developer: Prolacta Bioscience
Modality: Small Molecules
Administration: Oral

Overview

PBCLN-010 is a therapeutic formulation of human milk oligosaccharides (HMOs), a collection of approximately 200 structurally diverse sugars naturally found in high concentrations in human breast milk. Unlike nutritional components of breast milk, HMOs are not metabolized as an energy source by infants but instead guide the growth of appropriate bacteria in the gut, helping to train the immune system. PBCLN-010 is being investigated in combination with PBCLN-014 (Bifidobacterium longum subspecies infantis) as a therapy for patients with blood cancers undergoing allogeneic hematopoietic stem cell transplantation. Previous clinical trials have shown that this combination can safely and predictably control the gut microbiome in healthy adults.

Other names: Human Milk OligosaccharidesHMO

Beyond the preview

Go deeper on PBCLN-010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PBCLN-010.

Explore the full profile